Grifols

Diving into Grifols legacy, we're proud to share a remarkable chapter from our history that continues to inspire us. The pioneering work of Dr. Josep Antoni Grífols i Lucas in 1951 on plasmapheresis marked a turning point in medical science and the plasma industry. His dedication and innovative approach led to a landmark study involving over 350 donors, proving the safety ofthe procedure on donors. The findings presented at an international congress of transfusion medicine and published in the British Medical Journal the next year have been instrumental. It enabled the collection of plasma on a larger scale, offering the scientific community a technique that continues to be the most widespread method for obtaining plasma for the industrial fractionation process to the present day. His legacy continues to inspire us at Grifols as we forge ahead, innovating for patients. Learn more about our history of innovation 👉 http://spr.ly/6048c1YU0

On World Humanitarian Day, we honor the dedication of healthcare workers, volunteers, and aid workers worldwide. Their tireless efforts in the face of adversity inspire us at Grifols. We're proud to support global humanitarian initiatives through partnerships with Direct Relief, and the Red Cross and Red Crescent Movement, bringing aid this year to communities from Brazil's Rio Grande do Sul to the Israel/Gaza region. In times of crisis, the continuity of medical treatments is critical. We are committed to ensuring that those in need receive our essential medicines. Through Direct Relief, our donations have reached patients in Gaza, Ukraine and Cuba. Join us in celebrating these heroes and supporting our shared mission of humanitarian aid. #ActForHumanity #WorldHumanitarianDay #GrifolsSocialImpact

Today, we take you behind the scenes of our factory in Parets del Vallès, Spain, where we manufacture essential plasma-derived medicines. Taking us on this journey is Paula Segura, a manufacturing operator, who started at Grifols as a trainee and earned her first contract in the industry. Our people change lives while growing and developing into a forward-looking international company. #GrifolsTeam

Safety and quality are our priorities. Our vertically integrated production process guarantees the highest standards, from donation to delivery of the plasma-derived medicine to the patient. Grifols plasma centers are licensed and regulated by the U.S. FDA and other international agencies, and they are routinely inspected and certified by the International Quality Plasma Program (IQPP). In addition, we have one of the most innovative traceability systems, PediGri®, which enables healthcare professionals to see extensive manufacturing information at any time on the specific medicines they are administering to patients. It all starts at our donation centers. 👇 #GrifolsPlasma #PlasmaSourceOfLife

This month we celebrate 10 years of business activity in Honk Kong, a decade of dedication, growth, and excellence in supporting our Diagnostics division . Our Hong Kong team has been instrumental in establishing the APAC Financial Shared Service (APAC FSS) and fortifying compliance within the region. Their unwavering commitment has not only enhanced our operations but also solidified our presence in APAC. 🎉 祝賀香港團隊在過去十年所取得的成就，未來必將繼續成功！ #GrifolsHongKong #WeAreHealthcare

We are pleased to announce that GigaGen, a Grifols company, has received FDA approval to begin a Phase 1 trial to evaluate its recombinant polyclonal drug to treat and potentially clear hepatitis B virus infection (HBV). The therapeutic, containing more than 1,000 fully human recombinant anti-HBV antibodies that reproduce the human body’s natural immune response, marks a significant milestone for Grifols as part of its commitment to develop transformative antibody drugs for infectious diseases. For more information, see the press release 👉 https://lnkd.in/dseNnWzM #biotechnology #antibodies #WeAreInnovation 

We are proud to announce that the 2024 GATRA Award winner is Dr. Luis Muñoz Becerra, Senior Research Investigator Group Leader at FAU Erlangen-Nürnberg for his research project titled ¨Inhibition of serine proteases in tumor associated neutrophil extracellular traps (taNETs) by antithrombin¨. Founded in 2015, the GATRA Program is an annual international award to foster a scientific network and also the knowledge in the use of Antithrombin as a therapeutic product. More information here 👉 https://bit.ly/3LAJ2pa #hematology #clinicalresearch #GrifolsScientificAwards

Today we released our financial results for the second quarter of 2024, in which we accelerated our performance and reaffirmed guidance for the full year. We delivered revenues of EUR 1.8 billion (a 9% increase), an adjusted EBITDA of EUR 441 million (24.1%), positive free cash flow of EUR 57 million and a significant reduction of our leverage ratio, to 5.5x. We are focused on building on this strong performance, implementing our Cash Flow Improvement Plan, further reducing debt and executing operations effectively. Learn more here 👉 http://spr.ly/6048cvmrE

We are very pleased that the U.S. FDA has approved an expanded label for XEMBIFY® to include treatment-naïve patients with primary humoral immunodeficiencies. It is the first and only 20% subcutaneous immunoglobulin (SCIg) that enables patients to go straight to SCIg without initial intravenous Ig therapy. The extended label, which also includes biweekly dosing, provides patients with added flexibility and convenience. Increasing adoption of XEMBIFY is part of Grifols’ broader Ig business strategy focused on treating immunodeficiencies, which represent more than half of the total Ig market. For more information, see the press release. 👉 http://spr.ly/6048cWzfj #Immunology #WeAreInnovation

❤️ Voluntary plasma donations make the production of our medicines possible. With the largest network of donor centers in the world, we ensure that donations take place in highly controlled and secure environments. Choosing to make a plasma donation is a vital and very rewarding experience, but it’s also a commitment. 👉 We would like to show you the plasma donation process in one of our centers in the United States, one of the countries where donors receive a monetary compensation for their valuable time and effort. #GrifolsPlasma #PlasmaSourceOfLife